New data show excellent quality-of-life outcomes and effective tumor control for both intensity-modulated radiation therapy ...

Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. | ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Astellas is rolling out its first DTC campaign to raise awareness about an injection that treats geographic atrophy.

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Singlera Genomics and Astellas Pharma presented results during the JSOT 2024 Annual Meeting demonstrating that drug-induced ...

Discover Astellas Pharma's innovative patent for a stable pharmaceutical composition, enhancing cancer diagnostics with a unique antibody conjugate and precise formulation.

In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.

The Federal Circuit has vacated a District of Delaware ruling in a patent case which found that patent claims asserted by ...

Astellas Pharma announces US FDA listing of DIGITIVA for the management of heart failure: Tokyo Friday, September 20, 2024, 11:00 Hrs [IST] Astellas Pharma Inc. announced that DIG ...

Before companies and investors look towards the future, they must first understand the opportunities and challenges AI ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that DIGITIVA, a non-invasive digital health solution for heart failure management, has ...